Canaccord Genuity keeps Merit Medical at Buy and raises target to $121
Canaccord Genuity kept its Buy rating on Merit Medical Systems and raised its price target to $121 from $94. Source: TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Canaccord Genuity kept its Buy rating on Merit Medical Systems and lifted its price target to $121 from $94, a rise of 28.7%. According to TradingView, the stock closed at $86.24 on October 30, and the new target implies 40.3% upside from that level.
In the latest five analyst reports from the last 30 days, targets ranged from $90 to $110. JP Morgan kept an Overweight rating with a $110 target, Wells Fargo stayed at Equal-Weight with $92, Needham held Buy at $106, and BTIG held Buy at $110. Freedom Capital Markets initiated coverage on October 27 with an On Hold rating and a $90 target.
why it matters
Price target revisions are a routine part of the analyst research flow and rarely move markets on their own. They show how one brokerage values the shares, but they are not a forecast of the price. Comparing them with other brokers' targets shows how far analyst views diverge.
tags
instruments
sources
- Canaccord Genuity maintains Merit Medical Systems at Buy, raises price target to $121 from $94 — TradingView, 31 October 2026 at 00:36 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗